William C. Petersen Jr, MD
Research Interests: Novel therapeutics for childhood cancer patients, supportive care for childhood cancer patients.
William C. Petersen Jr., MD’s scientific interests include novel therapeutics and supportive care for childhood cancer patients. His research experience includes preclinical work in a neuro-oncology lab studying the tyrosine kinase inhibitor dasatinib and the aurora kinase inhibitor AT9283 and their in vivo and in vitro effects on medulloblastoma. These two agents were found to be individually efficacious in treating medulloblastoma, and to have synergistic effect when used in combination. He received formal training in novel therapeutics for pediatric cancer patients, obtaining a certificate in clinical and translational research while working as a member of the innovative therapeutics team at a Children’s Oncology Group Phase I-designated pediatric cancer center. He is developing multiple clinical trials for pediatric cancer patients, including a study of the soy compound, genistein, as an anti-toxicity agent in newly diagnosed pediatric cancer patients. He also is helping to develop translational studies investigating progesterone as a neuroprotectant for pediatric cancer patients receiving neurotoxic therapies such as brain irradiation and intrathecal chemotherapy. He is working to establish a novel therapeutics program at the University of Virginia Children’s Hospital, designed to offer early phase clinical trials for local and regional childhood cancer patients. He is also active in the planning and development of a regional multicenter consortium for novel pediatric cancer therapies.